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Alternative Treatment with Red Yeast Rice to Reduce Hyperlipidemia 
 Lisa Froemke, PA-S 
Physician Assistant Program, University of North Dakota School of Medicine & Health Sciences 
 
Abstract 
Introduction 
• Statins reduce lipid levels when lifestyle modifications are not adequate 
• Potential adverse effects of statins include myalgia and rhabdomyolysis  
• Non-compliance increases the risk of further atherosclerosis formation  
potentially leading to cardiovascular disease and related events  
• RYR has been utilized in China since the Tang Dynasty in 800 AD  
• Over the counter RYR has flourished in popularity with claims of being a 
natural product formed from cultured Monascus purpureus yeast on rice 
(See Figure 1), conveniently ordered online, and costing less than 
prescription statins  
• Clinicians desire alternative treatment options for patients to reduce non-
compliance that are effective and safe to reduce lipid levels and slow the 
progression of atherosclerosis 
 
Research Question 
Literature Review Applicability to Clinical 
Practice 
Acknowledgments  
Discussion 
 Childress et al. (2013) summarized RYR utilization has increased in 
popularity exponentially due the public’s perception of RYR being 
“natural” compared to prescription medication, perceived less side effects 
such as myalgia, reduced cost, over the counter availability, and lack of 
drug-drug interactions  
 Verhoeven et al. (2013) proposed less patient non-compliance with RYR 
due to reduced monthly cost of RYR $20-30 vs statins $120-300  
  Becker et al. (2013) reported 40% statin discontinuation within first year 
due to fear of adverse effects, cost, and reluctance to take medication 
chronically  
 Becker et al. (2009) trial demonstrated RYR had a significant reduction in 
LDL and total cholesterol when compared to placebo without increased 
myalgia making RYR a potential treatment option 
 Halbert et al. (2010) trial reflected RYR and pravastatin were tolerated 
equally with both groups experiencing recurrent myalgia and achieving 
comparable LDL cholesterol values therefore not supporting RYR as an 
alternative option 
 The meta-analysis conducted by Liu et al. (2006) evaluated RYR 
supplements (Cholestin, Xuezhikang, and Zhibituo) vs placebo.  reflecting 
the three RYR variations significantly reducing total cholesterol levels 
compared when compared to placebo over a 12 week duration (See Figure 
3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
– Figure 3: RYR supplements (Cholestin, Xuezhikang, and Zhibituo) vs 
placebo.  Adapted from “Chinese Medicine” (2006), Retrieved from: 
http://www.cmjournal.org/content/1/1/4 reflecting RYR significantly 
reducing total cholesterol levels  
 When 101 products containing RYR were reviewed none could be 
confirmed as passing any independent laboratory verification testing 
necessary to promote consistent composition of the active ingredient, 
monacolin, and no possible toxic byproducts including citrinin (Childress 
et al., 2013)  
 RYR supplements are not strictly regulated by the FDA due to being 
considered a food not a drug therefore side effects are not documented as 
systematically as prescription medications such as statins 
 Halbert et al. (2010) and Becker et al. (2009) highlight various RYR 
potency, unsupervised availability, and possible contamination with citrinin 
due to lack of consistency between different manufacturers supporting 
RYR is not safe for the general public’s consumption 
 Liu et al. (2006) assessed the safety concerns of not only the lack of 
regulation of red yeast rice preparation composition but also what is the 
recommended dosages and duration 
 Randomized trials prove RYR is effective in mild to moderate 
hyperlipidemia in various populations to lower LDL cholesterol, but it may 
not be sufficient to treat moderate to severe hyperlipidemia and should not 
be recommended for hyperlipidemia treatment (Gordon & Becker, 2011) 
• First line treatment of cardiovascular disease is lifestyle modification 
followed by the pharmacologic intervention of HMG-CoA reductase 
inhibitors or statins 
• Statins are commonly associated with intolerable side effects such as 
myalgia leading to medication non-compliance 
• RYR preparations claim to inhibit cholesterol synthesis without causing 
myalgia 
• RYR preparations have naturally occurring monacolins such as monacolin K 
which is chemically identical to lovastatin 
• RYR is not regulated by the FDA leading to questionable manufacturing 
practices producing varying ingredient composition 
• The purpose of this study is to investigate the role RYR in hyperlipidemia 
treatment compared to statins by evaluating efficacy, side effects, and the 
potential to reduce medication non-compliance in adults 
• Clinicians potentially could recommend RYR as an alternative treatment to 
hyperlipidemia in patients unable to comply with statin treatment to 
decrease cholesterol levels and reduce the progression of atherosclerosis 
 
 
 
 
• In patients with hyperlipidemia does RYR supplement as compared to statin 
treatment provide efficacious hypolipidemic results? 
 
 
 
 
 
 
 
 
 
• Figure 1: Red Yeast Rice 
PATHOPHYSIOLOGY OF HYPERLIPIDEMIA 
• Excess lipids form plaque in the arteries reducing blood flow (See Figure 4) 
• LDL cholesterol transfers cholesterol to cells in tissues and is equal to the risk of 
atherosclerosis in predicting coronary disease (Papadakis, Tierney, & McPhee, 
2011) 
• HDL cholesterol transfers cholesterol from the cells in tissues to be eliminated 
and  is inversely equal to the risk of atherosclerosis (Papadakis et al., 2011) 
• 11.5 years of life is projected to be lost in consequence to the development 
of atherosclerosis leading to coronary heart disease (Sikka et al., 2011). 
TREATMENT OPTIONS FOR HYPERLIPIDEMIA 
• Statin and RYR have similar pathophysiology due to sharing the same active 
ingredient, monacolin 
• MOA: Interfere with the conversion of Acetyl CoA to Mevalonate by inhibiting 
the enzyme HMG-CoA reductase (See Figure 2) (Verhoeven et al., 2013) 
• RYR comes in variations that do not have equal potency due to varying active 
potentials just as statins do not have equal potency when compared to each other 
(Musselman, Pettit, & Derenski, 2012) 
 
Acetyl CoA 
↓ 
HMG-CoA 
        RYR or Statins (Monacolins)→     ↓   ←HMG-CoA Reductase (Inhibited) 
Mevalonate 
↓ 
Cholesterol 
– Figure 2: Adapted from Applied Pharmacology by Bardal, Waechter, & Martin, 
2011 reflecting the effects of stains and RYR on cholesterol biosynthesis 
EFFICACY OF RYR THERAPY 
• RYR was compared to placebos such as the American Heart Step 1 Diet, 
phytosterol tablets, lifestyle changes, fish oil with all trials resulting in the 
reduction of total and LDL cholesterol that was superior or equal to placebo 
• The meta-analysis conducted by Liu et al. (2006) evaluated 93 randomized trials 
consisting of 9,625 participants utilizing three different variations of RYR 
preparations, Cholestin, Xuezhikang, and Zhibituo, with treatment duration 
ranging from 4 to 24 weeks with all 3 variations of RYR significantly reducing 
total cholesterol 
EFFICACY OF STATINS VS RYR 
• Three trials involving prescription statin intervention reflected a reduction in 
coronary events by 23-34% and coronary heart disease mortality by 20-42% 
(Yang & Mousa, 2012) 
• Becker et al. (2008) compared RYR to simvastatin reflecting significant LDL 
reduction without significant differentiation between test groups 
• Halbert et al. (2010) compared tolerability of pravastatin to RYR without 
significant difference in LDL reduction between test groups 
STATINS VS RYR SIDE EFFECTS  
• Statins are generally well tolerated, possible side effects include: myalgia, 
myositis, rhabdomyolysis, and hepatoxicity with 10-15% of statin users 
developing myalgias (Bardal et al., 2011) 
• 57% statin users experience myalgias when trying a second statin (Abd & 
Jacobson, 2011) 
• RYR side effects include: dizziness, decreased appetite, nausea, abdominal  pain, 
distension, and diarrhea occurring in 1.3-36% of patients (Liu et al., 2006) 
• Halbert et al. (2010) compared tolerability of pravastatin to RYR with 67% in 
RYR group reporting pain and 68% in the pravastatin group therefore similar 
tolerability 
STATINS VS RYR SAFETY 
• Heber et al. (2001) analyzed 9 different commercially available RYR products 
and discovered varying monacolin content from 0-0.58% and toxic citrinin 
byproduct in 7 out of 9 preparations 
• No studies are available regarding long-term cardiovascular prevention with RYR 
as with statin use 
• Statin safety concern addressed by the FDA ten years ago involved Bayer 
removing the statin, cerivastatin, after 31 patients died from rhabdomyolysis 
(Bardal et al., 2011) 
• Between 1987 and 2001 the FDA recorded 42 deaths or one death per million 30-
day supply prescriptions of statins from rhabdomyolysis (Sikka et al., 2011) 
 
  RYR has potential to reduce hyperlipidemia as reflected in short 
duration trials but at this time can not be recommended due to lack of 
standardization, long-term side effects, narrow test populations, and 
secondary cardiovascular prevention 
 RYR is not practical in healthcare setting due to lack of FDA 
regulation allowing for varying amounts of monacolin and potential 
toxic citrinin byproduct 
 Current FDA approved pharmacologic lipid modifying agents include niacin 
(vitamin B5), bile acid sequestrants, HMG-CoA reductase inhibitors, 
fibrates, and Ezetimibe with each group of agents having a unique 
mechanism of action to prevent further atherosclerosis (See Figure 4) 
 
 
 
 
 
 
 
 
 
 Figure 4: Atherosclerosis 
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• Cody Froemke, family, and friends for support and encouragement 
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Statement of the Problem 
• Studies are needed to determine if RYR supplement in the treatment of 
hyperlipidemia is a comparable treatment option to statins in efficacy, side 
effects, and safety to potentially reduce medication non-compliance. 
 
References 
Abd, T. T., & Jacobson, T. A. (2011). Statin-induced myopathy: A review and update. Expert Opinion on Drug Safety, 10(3), 373-387.  
 doi: 10.1517/14740338.2011.540568 
Bardal, S. K., Waechter, J. E., & Martin, D. S. (2011). Applied pharmacology. (pp. 114-118). St. Louis: Elsevier Saunders. 
Becker, D. J., French, B., Morris, P. B., Silvent, E., & Gordon, R. Y. (2013). Phytosterols, red yeast rice, and lifestyle changes instead of 
 statins: A  randomized, double-blinded, placebo-controlled trial. American Heart Journal, 166(1), 187-196.e2.  
 Retrieved from: http://dx.doi.org.ezproxy.library.und.edu/10.1016/j.ahj.2013.03.019 
Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009). Red yeast rice for dyslipidemia in statin-                           
 Intolerant patients: A  randomized trial. Annals of  Internal Medicine, 150(12), 830-839.  
 doi:10.7326/0003-4819-150-12-2 00906160-00006 
Becker, D. J., Gordon, R. Y., Morris, P. B., Yorko, J., Gordon, Y. J., Li, M., & Iqbal, N. (2008). Simvastatin vs therapeutic lifestyle 
 changes and supplements: Randomized primary prevention trial. Mayo Clinic Proceedings, 83(7), 758-764.  
 Retrieved from: http://www.mayoclinicproceedings.com.ezproxy.library.und.edu/ 
Childress, L., Gay, A., Zargar, A., & Ito, M. K. (2013). Review of red yeast rice content and current food and drug administration 
 oversight. Journal of  Clinical Lipidology, 7(2), 117-122.  
 Retrieved from: http://dx.doi.org.ezproxy.library.und.edu/10.1016/j.jacl.2012.09.003 
Gordon, R. Y., & Becker, D. J. (2011). The role of red yeast rice for the physician. Current Atherosclerosis Reports, 13(1), 73-80.  
 doi: 10.1007/s11883-010-0145-0 
Halbert, S. C., French, B., Gordon, R. Y., Farrar, J. T., Schmitz, K., Morris, P. B., Thompson, P. D., & Rader, D. J. (2010). Tolerability  of 
 red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. 
 The American Journal of Cardiology, 105(2), 198-204. doi: 10.1016/j.amjcard.2009.08.672 
Heber, D., Lembertas, A., Lu, Q. -., Bowerman, S., & Go, V. L. W. (2001). An analysis of nine proprietary chinese red yeast rice dietary 
 supplements: Implications of variability in chemical profile and contents. Journal of Alternative and Complementary 
 Medicine, 7(2), 133-139. Retrieved from: http://dx.doi.org.ezproxy.library.und.edu/10.1089/107555301750164181 
Liu, J., Zhang, J., Shi, Y., Grimsgaard, S., Alraek, T., & Fønnebø, V. (2006). Chinese red yeast rice (monascus purpureus) for primary  
 hyperlipidemia: A meta-analysis of randomized controlled trials. Chinese Medicine, 1.  
 Retrieved from: http://www.cmjournal.org/content/1/1/4 
Musselman, M. E., Pettit, R. S., & Derenski, K. L. (2012). A review and update of red yeast rice. Journal of Evidence-Based 
 Complementary and Alternative  Medicine, 17(1), 33-39. doi: 10.1177/2156587211429703 
Papadakis, M., Tierney, L., & McPhee, S. (2011). Current medical diagnosis and treatment. (52 ed., pp. 1245-1255). San Francisco: 
 Lange Medical Books/McGraw- Hill. 
Sikka, P., Kapoor, S., Bindra, V. K., Sharma, M., Vishwakarma, P., & Saxena, K. K. (2011). Statin intolerance: Now a solved problem. 
 Journal of  Postgraduate Medicine, 57(4), 321-328. doi: 10.4103/0022-3859.90085 
Verhoeven, V., Lopez Hartmann, M., Remmen, R., Wens, J., Apers, S., & Van Royen, P. (2013). Red yeast rice lowers cholesterol in 
 physicians - a double  blind, placebo controlled randomized trial. BMC Complementary and Alternative Medicine, 13. 
 Retrieved from: http://www.biomedcentral.com/1472-6882/13/178 
Yang, C. W., & Mousa, S. A. (2012). The effect of red yeast rice (monascus purpureus) in dyslipidemia and other disorders. 
 Complementary Therapies in Medicine, 20(6), 466-474.  
 Retrieved from: http://dx.doi.org.ezproxy.library.und.edu/10.1016/j.ctim.2012.07.004 
